Prospective study of the effects of antiretroviral therapy on kaposi sarcoma - Associated herpesvirus infection in patients with and without kaposi sarcoma

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue 4, 2002, Pages 384-390

  Gill, Jasjit ^a   Bourboulia, Dimitra ^b   Wilkinson, John ^a   Hayes, Peter ^a   Cope, Alethea ^b   Marcelin, Anne Genevieve ^c   Calvez, Vincent ^c   Gotch, Frances ^a   Boshoff, Christopher ^b   Gazzard, Brian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antiretroviral therapy; Herpesvirus; Kaposi sarcoma

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER REGRESSION; CLINICAL ARTICLE; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENERAL CONDITION IMPROVEMENT; HERPES VIRUS INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIREMIA; VIRUS LOAD;

EID: 0036891963     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200212010-00003     Document Type: Article

References (51)

1. Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996;335:233-41.
2. Kedes DH, Operskalski E, Ganem D, et al. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 1996;2:918-24.
3. Miller G, Rigsby MO, Heston L, et al. Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med 1996;334:1292-7.
4. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276-80.
5. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186-91.
6. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95:1406-12.
7. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpes-virus infects monotypic (IgMλ) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001;97:2130-6.
8. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998;391:86-9.
9. Swanton C, Mann DJ, Fleckenstein B, et al. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 1997;390:184-7.
10. Cheng EH, Nicholas J, Bellows DS, et al. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci USA 1997;94:690-4.
11. Gao S, Boshoff C, Jayachandra S, et al. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signalling pathway. Oncogene 1997;15:1979-85.
12. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997; 278:290-3.
13. Thome M, Schneider P, Hofmann K, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997;386:517-21.
14. Lee H, Veazy R, Williams K, et al. Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med 1998;4:435-40.
15. Muralidhar S, Pumfery AM, Hassani M, et al. Identification of kaposin open reading frame (K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J Virol 1998;72:4980-8.
16. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000;6:1121-7.
17. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994;371:674-80.
18. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92: 1823-30.
19. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study. BMJ 1999;319:23-4.
20. Lebbé C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998;12:F45-9.
21. Martinelli C, Zazzi M, Ambu S, et al. Complete regression of AIDS-related Kaposi's sarcoma-associated herpesvirus-8 during therapy with indinavir. AIDS 1998;12:1717-9.
22. Niehues T, Homeff G, Megahed M, et al. Complete regression of AIDS-related Kaposi's sarcoma in a child treated with highly active antiretroviral therapy. AIDS 1999;13:1148-9.
23. Shaw AJ, McLean KA. Kaposi's sarcoma regression following treatment with a triple antiretroviral regimen containing nevirapine. Int J STD AIDS 1999;10:417-8.
24. Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 1997;11:261-2.
25. Parra R, Leal M, Delgado J, et al. Regression of invasive AIDS-related Kaposi's sarcoma following antiretroviral therapy. Clin Infect Dis 1998;26:218-9.
26. Reitz MS, Nerurkar LS, Gallo RC. Perspective on Kaposi's sarcoma: Facts, concepts, and conjectures. J Natl Cancer Inst 1999; 91:1453-8.
27. Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS 2000;14:987-93.
28. Rizzieri DA, Liu J, Traweek ST, et al. Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor. Lancet 1997;349:775-6.
29. De Milito A, Catucci M, Venturi G, et al. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1-and human herpesvirus 8-coinfected patients. J Med Virol 1999; 57:140-4.
30. Torre-Cisneros J, Pozo F, Serrano R, et al. Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin. AIDS 2000;14:2215-7.
31. Leao JC, Kumar N, McLean KA, et al. Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients. J Med Virol 2000;62:416-20.
32. Burdick AE, Carmichael C, Rady PL, et al. Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus-8 DNA in a patient with AIDS after protease inhibitor therapy. J Am Acad Dermatol 1997;37:648-9.
33. Wit FWNM, Sol CJA, Renwick N, et al. Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. AIDS 1998;12:218-9.
34. Blum L, Pellet C, Agbalika F, et al. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. AIDS 1997;11:1653-4.
35. Wilkinson J, Cope A, Gill J, et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002;76:2634-40.
36. Krown SE, Metroka C, Wernz, for the AIDS Clinical Trials Group. Kaposi's sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989;7:1201-7.
37. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996;2:925-8.
38. Whitby D, Luppi M, Barozzi P, et al. HHV-8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst 2001;90:395-7.
39. Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 1996;349:1133-8.
40. Sitas F, Carrara H, Beral V, et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med 1999;340:1863-71.
41. Lallemand F, Desire N, Rozenbaum W, et al. Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay. J Clin Microbiol 2000;38:1404-8.
42. Bieche I, Olivi M, Champeme MH, et al. Novel approach to quantitative polymerase chain reaction using real-time detection: Application to the detection of gene amplification in breast cancer. Int J Cancer 1998;78:661-6.
43. Holland PM, Abramson RD, Watson R, et al. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 1991;88:7276-80.
44. Boivin G, Gaudreau A, Toma E, et al. Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: Correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy. Antimicrob Agents Chemother 1999;43:377-80.
45. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995;346:799-802.
46. Chatlynne LG, Lapps W, Handy M, et al. Detection and titration of human herpesvirus-8-specific antibodies in sera from blood donors, acquired immunodeficiency syndrome patients, and Kaposi's sarcoma patients using a whole virus enzyme-linked immunosorbent assay. Blood 1998;92:53-8.
47. Goudsmit J, Renwick N, Dukers NHTM, et al. Human herpesvirus 8 infections in the Amsterdam Cohort studies (1984-1997): Analysis of seroconversions to orf65 and orf73. Proc Natl Acad Sci USA 2000;97:4838-43.
48. Caterino-de-Araujo A, Carbone PHL, Martinelli FLB, et al. Absence of an association between the presence of human herpesvirus 8 antibodies and the development of Kaposi's sarcoma in HIV-1-infected patients receiving antiretroviral therapy. AIDS 2000;14: 1455-7.
49. Campbell TB, Borok M, Gwanzura L, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000;14:2109-16.
50. Osman M, Kubo T, Gill J, et al. Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol 1999;73:6136-40.
51. Brander C, O'Connor P, Suscovich T, et al. Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma associated herpesvirus kaposin protein. J Infect Dis 2001;184:119-26.